MetLife Investment Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $19.2M | Buy |
184,164
+5,209
| +3% | +$544K | 0.11% | 158 |
|
|
2025
Q1 | $20.9M | Buy |
178,955
+156,678
| +703% | +$18.3M | 0.11% | 146 |
|
|
2024
Q4 | $1.88M | Buy |
22,277
+1,232
| +6% | +$104K | 0.01% | 1075 |
|
|
2024
Q3 | $1.89M | Hold |
21,045
| – | – | 0.01% | 1047 |
|
|
2024
Q2 | $1.69M | Buy |
21,045
+2,542
| +14% | +$205K | 0.01% | 1060 |
|
|
2024
Q1 | $1.48M | Hold |
18,503
| – | – | 0.01% | 1090 |
|
|
2023
Q4 | $1.47M | Hold |
18,503
| – | – | 0.01% | 1103 |
|
|
2023
Q3 | $1.29M | Buy |
18,503
+1,282
| +7% | +$89.6K | 0.01% | 1103 |
|
|
2023
Q2 | $1.24M | Buy |
17,221
+321
| +2% | +$23.1K | 0.01% | 1146 |
|
|
2023
Q1 | $1.04M | Hold |
16,900
| – | – | 0.01% | 1208 |
|
|
2022
Q4 | $1.3M | Buy |
16,900
+558
| +3% | +$43K | 0.01% | 1083 |
|
|
2022
Q3 | $729K | Sell |
16,342
-1,006
| -6% | -$44.9K | 0.01% | 1370 |
|
|
2022
Q2 | $664K | Hold |
17,348
| – | – | 0.01% | 1474 |
|
|
2022
Q1 | $718K | Buy |
17,348
+6,439
| +59% | +$267K | ﹤0.01% | 1544 |
|
|
2021
Q4 | $412K | Hold |
10,909
| – | – | ﹤0.01% | 1610 |
|
|
2021
Q3 | $360K | Hold |
10,909
| – | – | ﹤0.01% | 1717 |
|
|
2021
Q2 | $736K | Hold |
10,909
| – | – | 0.01% | 1347 |
|
|
2021
Q1 | $618K | Hold |
10,909
| – | – | 0.01% | 1400 |
|
|
2020
Q4 | $889K | Sell |
10,909
-1,403
| -11% | -$114K | 0.01% | 1193 |
|
|
2020
Q3 | $877K | Hold |
12,312
| – | – | 0.01% | 1092 |
|
|
2020
Q2 | $1.01M | Buy |
12,312
+680
| +6% | +$56K | 0.01% | 1027 |
|
|
2020
Q1 | $684K | Buy |
11,632
+962
| +9% | +$56.6K | 0.01% | 1059 |
|
|
2019
Q4 | $1.1M | Sell |
10,670
-1,027
| -9% | -$106K | 0.01% | 1054 |
|
|
2019
Q3 | $237K | Hold |
11,697
| – | – | ﹤0.01% | 1850 |
|
|
2019
Q2 | $301K | Buy |
+11,697
| New | +$301K | ﹤0.01% | 1784 |
|